...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: OUCH!!! Things Move Faster In The Cancer Arena and Other Gems

SF, give it rest for once,  if you are a long time holder than these Zenith shares were given for free,  who cares what they  are worth now or not, At some point in the future 1 or 2 or 5  years if the science proves right the shares will be worth alot and they will be bought out at some point in the next few years or sooner ,  Just remember  what pfizer paid for Medivation 2 years ago  $14 billion, and give patients 6 months longer to live,  Zen 3694 to this point enhances and makes enzalutamide a better drug. Have some fricken paitence  , It takes time to get a drug to market. I will wait the few years to get 1/2 of what pfizer paid  Medivation .

Share
New Message
Please login to post a reply